Skip to main content
. Author manuscript; available in PMC: 2014 Sep 12.
Published in final edited form as: Nat Commun. 2014 Mar 12;5:3459. doi: 10.1038/ncomms4459

Figure 5. Therapeutic effect of MePS2-1 siGRAMD1B in vitro and in vivo.

Figure 5

(a) Knockdown of GRAMD1B using UM and MePS2-1 modified siRNAs (40 nM, 10% FBS-containing media) (n=1). (b) Intracellular binding of UM and MePS2-1 siGRAMD1B to Ago2 in HeyA8-MDR cells (50 nM, serum-free condition). (c) Effect of MePS2-1 siGRAMD1B on tumoral response to paclitaxel treatment in HeyA8-MDR orthotopic ovarian cancer mouse model. (d) Knockdown of GRMAD1B by MePS2-1-siGRAMD1B-DOPC in HeyA8-MDR tumors. (e) Caspase 3 activity in tumors treated with MePS2-1-siCon-DOPC or MePS2-1-siGRAMD1B-DOPC +/- paclitaxel. Scale bar represents 100 μm. (f) Effect of MePS2-1 siGRAMD1B on tumoral response to paclitaxel treatment in SKOV3-TR orthotopic ovarian cancer mouse model. [P-values obtained with Student’s t-test; (b) ***, P<0.001, compared to UM si GRAMD1B (n=3); (c, f) *, P<0.05 or **, P<0.01, compared to the corresponding control groups (n=10); (d) **, P<0.01, compared to MePS2-1-siCon-DOPC group (n=2-3); (e), ****, P<0.0001, compared to paclitaxel or MePS2-1-siGRAMD1B-DOPC monotherapy groups (n=10); bars and error bars represent mean values and the corresponding S.E.M.s].